Filament’s Biogen BIIB Stock Holding History

Filament’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,200	Closed	-$312K	–	37
2016 Q1	$312K	Sell	1,200 -260	-18%	-$68.7K	0.15%	39
2015 Q4	$447K	Buy	+1,460	New	+$420K	0.22%	29

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Filament's BIIB Position: Q2 2016 in Review

Filament sold out of Biogen (BIIB) in Q2 2016, closing a stake of 1,200 shares — an estimated $312K sold.

Filament first reported a position in BIIB in Q4 2015 and held it in 2 quarters. The position peaked at $447K in Q4 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

Filament reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
Filament sold 1,200 Biogen shares in Q2 2016, an estimated $312K.
Filament first reported a position in Biogen in Q4 2015 and held it in 2 quarters.
Filament's Biogen position peaked at $447K in Q4 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Filament's 13F filing for Q2 2016, filed 28 Jul 2016.